1/10/2012 8:44:26 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies. The agreement includes the technology transfer and cGMP production of Trophogen’s recombinant, more potent/efficacious and longer acting human follicle-stimulating hormone (rhFSH) analog. The analog is the lead compound developed through Trophogen’s proprietary superagonist hormone technology platform originally licensed from the National Institutes of Health. The program is funded by a National Institute for Child Health & Human Development (NICHD) Phase 2 competitive renewal SBIR grant for $3 million over a 3 year period.
comments powered by